Mitomycin instillation to prevent recurrence of superficial bladder carcinoma. Results of a controlled, prospective study in 58 patients.
In a prospective randomized study, 58 patients with superficial bladder carcinoma received, after transurethral resection (TUR), either no further therapy (30 patients) or mitomycin at 20 mg/20 ml instilled every 2 weeks for the first year and every 4 weeks for the second year starting 3-4 weeks after TUR (28 patients). Bladder tumors recurred in only 2 patients in the treatment group; 15 patients in the control group had recurrences, with increases in grade in 4 patients and in stage in 6 patients. 3 patients in the control group developed metastases, including 1 who died of his tumor; there were no tumor-related deaths in the mitomycin group.
D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008937:Mitomycins / Q000008:administration & dosage* / Q000627:therapeutic use; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D011183:Postoperative Complications / Q000517:prevention & control; D011446:Prospective Studies; D011897:Random Allocation; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000601:surgery
D008937:Mitomycins